Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...
On 4, 2024, Amgen, Inc. filed a notice of data breach with the Attorney General of Massachusetts after discovering that ...
Federman & Sherwood investigates Amgen, Inc. for data breach. Amgen became aware of a cybersecurity incident that involved one of their service providers, Sirva Relocation, LLC and its parent company ...
Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded ...
Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...
As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...
Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering ...
Beyond MariTide, Amgen has a rich pipeline with more than 30 phase 3 programs. Some are for existing medicines seeking label ...
Amgen (AMGN) shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and ...
Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback